BROOMFIELD, Colo., Oct. 4 /PRNewswire/ -- Accera Inc., a privately held biotechnology company focused on developing novel drugs for neurodegenerative diseases, announced today that the company will be participating in the 4th Annual BIO Investor Forum next week at the Palace Hotel in San Francisco:
-- Dr. Lauren Costantini, Vice President of Clinical Development, will
contribute to the panel discussion, "Alzheimer's Disease - Novel
Mechanisms and Targets Renewing the Future of Patients" on Wednesday,
October 10 at 9:10 a.m. PDT.
-- Dr. Steve Orndorff, President and CEO, will present on Thursday,
October 11 at 11:00 a.m. PDT.
Dr. Orndorff will provide an overview of Accera and its technology platform as well as a summary of the positive data from the company's Phase IIb studies of its lead therapeutic product, Ketasyn(TM) (AC-1202) in Alzheimer's disease (AD) and age-associated memory impairment (AAMI). In both studies, Ketasyn was shown to significantly improve memory and cognition using a battery of neuropsychometric tests, including ADAS-Cog, the FDA's gold- standard efficacy measure for AD drugs. Ketasyn was also well tolerated in both indications, even when taken in addition to existing AD drugs, making it a promising candidate for a cotherapeutic approach to treating AD.
About Accera, Inc.
Based in Broomfield, CO, Accera, Inc. is a privately held biotechnology
company focused on developing novel drugs for neurodegenerative diseases.
The company's lead candidate, Ketasyn(TM) (AC-1202), is a first-in-class
molecule that earlier this year completed successful Phase II clinical
trials for Alzheimer's disease and age-associated memory impairment (AAMI).
A key element of Accera's strategy is to develop AC-1202 and other
proprietary small molecule compounds in its pipeline with corporate
partners for a range of memory and cognition disorders associated with
neurological conditions and aging. '/>"/>
|SOURCE Accera Inc.|
Copyright©2007 PR Newswire.
All rights reserved